Invention Application
![CRYSTAL FORM S4 OF THE PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)- 1 H-IMIDAZOL-6- YL)-5'-METHOXYSPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONE FUMARATE](/docs/US/2022-06-30/US20220204494A1/abs.jpg.600x600.jpg)
- Patent Title: CRYSTAL FORM S4 OF THE PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)- 1 H-IMIDAZOL-6- YL)-5'-METHOXYSPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONE FUMARATE
-
Application No.: US17605108Application Date: 2020-04-23
-
Publication No.: US20220204494A1Publication Date: 2022-06-30
- Inventor: Sze-Wan Li , Mark Robert Bray
- Applicant: UNIVERSITY HEALTH NETWORK
- Applicant Address: CA Toronto
- Assignee: UNIVERSITY HEALTH NETWORK
- Current Assignee: UNIVERSITY HEALTH NETWORK
- Current Assignee Address: CA Toronto
- International Application: PCT/CA2020/050535 WO 20200423
- Main IPC: C07D413/14
- IPC: C07D413/14
![CRYSTAL FORM S4 OF THE PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)- 1 H-IMIDAZOL-6- YL)-5'-METHOXYSPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONE FUMARATE](/abs-image/US/2022/06/30/US20220204494A1/abs.jpg.150x150.jpg)
Abstract:
Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1:0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2°±0.2 in 2θ.
Information query
